There are 2867 resources available
809P - Outcomes of patients with resected stage III/IV acral or mucosal melanoma treated with adjuvant anti-PD-1 therapy
Presenter: Sarah Kay Jacques
Session: Poster session 03
1081P - DNA damage response and repair (DDR) gene mutations as an alternative mechanism to generate high TMB in never smoker NSCLC patients
Presenter: Marco Filetti
Session: Poster session 15
1494P - Regomune - a phase II study of regorafenib + avelumab in solid tumors: Results of the soft tissue sarcoma (STS) cohort
Presenter: Sophie Cousin
Session: Poster session 11
810P - PRESERV MEL: Real-world outcomes and health-related quality of life (HRQoL) in patients receiving adjuvant nivolumab for melanoma in Belgium and Luxembourg
Presenter: Anne Rogiers
Session: Poster session 03
1082P - Improved response prediction to immune checkpoint inhibitors by combining TMB and WGS-driven genomic features in NSCLC
Presenter: Paulina Nawrocka-Muszyńska
Session: Poster session 15
1495P - SAKK 57/16 nab-paclitaxel and gemcitabine in soft tissue sarcoma (NAPAGE): Final results from the phase Ib/II trial with >2y median follow up
Presenter: Antonia Digklia
Session: Poster session 11
811P - Three-years real-world evidence of adjuvant dabrafenib plus trametinib (DT) in patients with resected melanoma in Spain (GEM 1901 - DESCRIBE-AD)
Presenter: Pablo Cerezuela-Fuentes
Session: Poster session 03
1496P - Trabectedin for patients with advanced soft tissue sarcoma: A non-interventional, prospective, multicenter study
Presenter: Viktor Gruenwald
Session: Poster session 11
1083P - The analysis molecular characteristics, PD-L1, TMB and MSI in Chinese NF1-mutated NSCLC
Presenter: jun Liu
Session: Poster session 15